Overview
- Addresses key issues relating to the increasing expenditure on new targeted cancer therapies
- Discusses the evaluation of benefits, harms, and costs
- Examines drug pricing and drug price regulation in different countries
- Explores the changing landscape in marketing authorization and its regulation
Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 213)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (12 chapters)
-
Front Matter
Keywords
About this book
This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society’s willingness to pay.
Reviews
Editors and Affiliations
About the editor
Dr. Evelyn Walter has been head (and co-founder) of the Institute of Pharmaeconomic Research (IPF) in Vienna since 2003. The IPF’s main areas include health economic evaluation, modeling, and expert advice on reimbursement decisions, pharmaceutical pricing and distribution. She first studied Mathematics at Vienna University of Technology, before switching to the Vienna University of Economic Sciences, where she completed a Master’s and a doctorate in Economics. She has authored or co-authored some 60 publications, chiefly in refereed journals, and serves as a reviewer for several health economics journals. In Austria, she initiated the “Guidelines for Health Evaluation.” She is a Member of the Scientific Advisory Board for the “System of Health Accounts” at Statistic Austria. As a member of ISPOR (the International Society of Pharmacoeconomics and outcome Research) she co-chaired the 17th and 18th Annual European Congresses. Dr. Walter is a Lecturer at the University of Applied Sciences in Burgenland, where she teaches courses on Health Economics, Health Technology Assessment and Pharma Management.
Bibliographic Information
Book Title: Regulatory and Economic Aspects in Oncology
Editors: Evelyn Walter
Series Title: Recent Results in Cancer Research
DOI: https://doi.org/10.1007/978-3-030-01207-6
Publisher: Springer Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Switzerland AG 2019
Hardcover ISBN: 978-3-030-01206-9Published: 23 January 2019
eBook ISBN: 978-3-030-01207-6Published: 13 December 2018
Series ISSN: 0080-0015
Series E-ISSN: 2197-6767
Edition Number: 1
Number of Pages: VII, 205
Number of Illustrations: 2 b/w illustrations, 12 illustrations in colour
Topics: Oncology, Health Administration